EUVIMEDEUVIMED entdecken
Crossref

Fragment Addition-Based Design of Heteroaromatic-Biphenyl-DAPYs as Potent and Orally Available Non-nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Enhanced Safety

Wen-Juan Huang, Christophe Pannecouque, Erik De Clercq iD, Shuai Wang iD, Fen-Er Chen iD

Journal of Medicinal Chemistry · 10.10.2024 · 67 (19) · 17568-17584

DOI: 10.1021/acs.jmedchem.4c01571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 01.10.2024. Verfasst von Wen-Juan Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Reverse Transcriptase Inhibitors, HIV-1, Drug Design, Biphenyl Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our previously disclosed biphenyl-DAPY 3 emerged as a potent inhibitor against WT HIV-1 and various mutant strains. Yet, its journey toward clinical application was thwarted by pronounced cytotoxicity and low selectivity (CC50 = 6 μM, SI = 3515). The safety improvement approach we employed in this work entailed the incorporation of diverse heteroaromatic substituents at the C5 position to exploit the tolerant regions of the NNRTIs' binding pocket through fragment addition-based drug design strategy, ultimately leading to the identification of a series of novel heteroaromatic-biphenyl-DAPYs. The exemplary compound 10d revealed a striking reduction in cytotoxicity (CC50 > 272.81 μM), nearly 45.5 times lower than 3, while showcasing 15-fold increase in selectivity (SI > 52632). This analog sustained exceptional anti-HIV-1 activity against both WT HIV-1 (EC50 = 5 nM) and various mutant strains. Compared to 3, a markedly slower rate of metabolism in human liver microsomes of 10d was observed. Its pharmacokinetic profile was equally captivating, featuring excellent oral bioavailability (F = 57.4%). Moreover, 10d exhibited a delicate sensitivity toward CYP, minimal inhibition of hERG, and no detectable acute toxicity in vivo. These enchanting findings illuminated the potential of 10d as a promising candidate for HIV-1 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reverse Transcriptase InhibitorsHIV-1Drug DesignBiphenyl CompoundsHumansAnimalsStructure-Activity RelationshipHIV Reverse TranscriptaseAdministration, OralAnti-HIV AgentsMicrosomes, LiverRatsMaleRats, Sprague-Dawley

Substanzen

Reverse Transcriptase InhibitorsBiphenyl CompoundsHIV Reverse TranscriptaseAnti-HIV Agentsbiphenyl

Autor:innen und Institutionen

  • Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.
  • Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, China.
  • Rega Institute for Medical Research, KU Leuven, Herestraat 49, Leuven B-3000, Belgium.

ORCID-Profile: Erik De Clercq, Shuai Wang, Fen-Er Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, W. J., Pannecouque, C., De Clercq, E., Wang, S., & Chen, F. E. (2024). Fragment Addition-Based Design of Heteroaromatic-Biphenyl-DAPYs as Potent and Orally Available Non-nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Enhanced Safety. Journal of Medicinal Chemistry, 67(19), 17568-17584. https://doi.org/10.1021/acs.jmedchem.4c01571

Vancouver

Huang WJ, Pannecouque C, De Clercq E, Wang S, Chen FE. Fragment Addition-Based Design of Heteroaromatic-Biphenyl-DAPYs as Potent and Orally Available Non-nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Enhanced Safety. Journal of Medicinal Chemistry. 2024;67(19):17568-17584. doi:10.1021/acs.jmedchem.4c01571

BibTeX
@article{Huang2024,
  author = {Huang, Wen-Juan and Pannecouque, Christophe and De Clercq, Erik and Wang, Shuai and Chen, Fen-Er},
  title = {Fragment Addition-Based Design of Heteroaromatic-Biphenyl-DAPYs as Potent and Orally Available Non-nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Enhanced Safety},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {19},
  pages = {17568--17584},
  doi = {10.1021/acs.jmedchem.4c01571}
}
Kostenlos starten →